https://doi.org/10.4081/uij.2024.328

The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study

Vol. 36 No. 1 (2024)
Published: 12 December 2024
Overactive bladder, oxybutynin hydrochloride, intravesical administration, urinary catheterization, antimuscarinic
Abstract Views: 1011
PDF: 271
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Shoeb Alahmad
shuaib.ahmad@wpu.edu.sy
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Al-Watanyia Private University, Hama, Syrian Arab Republic.
Rawaa AlKayali
Department of Biochemistry and Microbiology, Faculty of Pharmacy, Aleppo University, Syrian Arab Republic.
Lubana Alkhoder
Department of Laboratory Diagnosis, Faculty of Pharmacy, Al-Watanyia Private University, Hama, Syrian Arab Republic.
Gihad Allugamie
Department of Urology, Hama Hospital, Ministry of Health, Hama, Syrian Arab Republic.

Overactive bladder (OAB) syndrome is a chronic, debilitating disorder with physical, psychological, and social repercussions that considerably reduces the quality of life for 12-17% of the population. Despite the emergence of novel antimuscarinic medicines, many OAB syndrome patients are unable to tolerate or respond to oral treatment. Oxybutynin hydrochloride (OH) is one of the most essential medications available. The purpose of this article is to investigate the efficacy of intravesical OH in treating patients with OAB who are unresponsive to oral medication or who experience intolerable systemic side effects of anticholinergic drugs. OH was administered intravesically to 48 patients with neurogenic bladder and incontinence more than 8 times a day. Treatment consisted of dissolving 5 mg OH tablets in sterile saline, 40 mL, once a week. The duration of intravesical treatment with OH was applied once a week for 4 weeks. The rate of improvement was remarkable, and the best response was 70% in all 48 patients. Cystometrography was performed and revealed that cystocapacity before and after the initial modified intravesical oxybutynin was 123.41±24.83 and 308.08±30.68, respectively. One patient complained of slight pain in the lower abdomen, but this effect gradually subsided as treatment continued. The patient continued the entire treatment with four doses. These encouraging results indicate that intravesical instillation of OH is an attractive, effective, and safe alternative therapy in patients with neurogenic bladder who either do not respond or have intolerable side effects from oral medications.

Altmetrics

Downloads

Download data is not yet available.
Leron E, Weintraub AY, Mastrolia SA, Schwarzman P: Overactive bladder syndrome: evaluation and management. Curr Urol 2018;11:117‑25. DOI: https://doi.org/10.1159/000447205
Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population‑based prevalence study. BJU Int 2001;87:760‑6. DOI: https://doi.org/10.1046/j.1464-410x.2001.02228.x
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol 2010;21:5-26. DOI: https://doi.org/10.1007/s00192-009-0976-9
Drake MJ: Do we need a new definition of the overactive bladder syndrome? ICI‑RS 2013. Neurourol Urodyn 2014;33:622‑4. DOI: https://doi.org/10.1002/nau.22609
Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherencenof anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J. Urology 2021:205:1595-604. DOI: https://doi.org/10.1097/JU.0000000000001440
Escobar CM, Falk KN, Mehta S, et al. Rethinking second-line therapy for overactive bladder to improve patient access to treatment options. Obstet Gynecol 2021:137:454-60. DOI: https://doi.org/10.1097/AOG.0000000000004279
Cakir SS, Degirmentepe RB, Atalay HA, et al. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study. Int Urol Nephrol 2019;51:27-32. DOI: https://doi.org/10.1007/s11255-018-2030-7
Yoshimura N, Chancellor MB. Current and future pharmacological treatment of overactive bladder. J Urol 2002;168:1897-913. DOI: https://doi.org/10.1016/S0022-5347(05)64261-9
Noh JW, Lee B, Kim JH. Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis. Int Urol Nephrol 2019;51:1459-71. DOI: https://doi.org/10.1007/s11255-019-02209-y
Jurgen P, Hans J, Uwe B, Theodor S. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000;55:358-62. DOI: https://doi.org/10.1016/S0090-4295(99)00540-3
Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol 2002;36:18-24. DOI: https://doi.org/10.1080/003655902317259319
Crane A, Isharwal S, Zhu H. Current therapeutic strategies in clinical urology. Mol Pharm 2018;15:3010-9. DOI: https://doi.org/10.1021/acs.molpharmaceut.8b00383
Schroder A, Albrecht U, Schnitker J, et al. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodyn 2016;35:582-8. DOI: https://doi.org/10.1002/nau.22755
Guerra LA, Moher D, Sampson M, et al. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol 2008;180:1091-7. DOI: https://doi.org/10.1016/j.juro.2008.05.056
Lazarus J. Intravesical oxybutynin in the pediatric neurogenic bladder. Nat Rev Urol 2009;6:671-4. DOI: https://doi.org/10.1038/nrurol.2009.214
Mizunaga M, Miyata M, Kaneko S, et al. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Paraplegia 1994;32:25-9. DOI: https://doi.org/10.1038/sc.1994.5
Kennelly. MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 2010;12:12-9.
Jacoby HI. Gastric emptying. In: Reference Module in Biomedical Sciences; 2017. DOI: https://doi.org/10.1016/B978-0-12-801238-3.64921-8
Kasabian NG, Vlachiotis JD, Lais A, et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyper-reflexia. J Urol 1994;151:944-5. DOI: https://doi.org/10.1016/S0022-5347(17)35130-3
Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992;148:595-7. DOI: https://doi.org/10.1016/S0022-5347(17)36663-6
Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998;160:892-6. DOI: https://doi.org/10.1097/00005392-199809010-00084
Madersbacher, H. Control of detrusor hyperreflexia by intravesical instillation of oxybutynin hydrochloride. Paraplegia 1991:29:84-90. DOI: https://doi.org/10.1038/sc.1991.11
O’Flynn KJ, Thomas DG. Intravesical instillation of oxybutynin hydrochloride for detrusor hyperreflexia. Br J Urol 1993;72:566-70. DOI: https://doi.org/10.1111/j.1464-410X.1993.tb16210.x
Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 1996;34:284-7. DOI: https://doi.org/10.1038/sc.1996.51

How to Cite



The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study. (2024). Urogynaecologia, 36(1). https://doi.org/10.4081/uij.2024.328
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

51-60 of 96

You may also start an advanced similarity search for this article.